Discordance between Fasting Plasma Glucose (FPG) and HbA1c in Diagnosing Diabetes and Pre-diabetes in The Malaysian Cohort

Nor Azian Abdul Murad,¹ Noraidatulakma Abdullah,¹ Mohd Arman Kamaruddin,¹ Nazihah Abd Jalal,¹ Norliza Ismail,¹ Nurul Ain Mhd Yusof,¹ Norlaila Mustafa,² Rahman Jamal¹

¹UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia
²Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia

Abstract

Objective. In this present study, we aim to evaluate the accuracy of the HbA1c relative to fasting plasma glucose (FPG) in the diagnosis of diabetes and pre-diabetes among The Malaysian Cohort (TMC) participants.

Methodology. FPG and HbA1c were taken from 40,667 eligible TMC participants that have no previous history of diabetes, aged between 35-70 years and were recruited from 2006 – 2012. Participants were classified as normal, diabetes and pre-diabetes based on the 2006 World Health Organization (WHO) criteria. Statistical analyses were performed using ANOVA and Chi-square test, while Pearson correlation and Cohen’s kappa were used to examine the concordance rate between FPG and HbA1c.

Results. The study samples consisted of 16,224 men and 24,443 women. The prevalence of diabetes among the participants was 5.7% and 7.5% according to the FPG and HbA1c level, respectively. Based on FPG, 10.6% of the participants had pre-diabetes but this increased to 14.2% based on HbA1c (r=0.86; P<0.001). HbA1c had a sensitivity of 58.20 (95% CI: 56.43, 59.96) and a specificity of 98.59 (95% CI: 98.46, 98.70).

Conclusion. A higher prevalence of pre-diabetes and diabetes was observed when using HbA1c as a diagnosis tool, suggesting that it could possibly be more useful for early detection. However, given that HbA1c may also have lower sensitivity and higher false positive rate, several diagnostic criteria should be used to diagnose diabetes accurately.

Key words: type 2 diabetes mellitus, fasting plasma glucose, HbA1c, The Malaysian Cohort, diagnosis, population differences

INTRODUCTION

The prevalence of Type 2 diabetes mellitus (T2DM) has been increasing worldwide. It is projected that approximately 300 million people will be diagnosed with T2DM by 2025.¹ Malaysia has also observed tremendous hikes in the number of T2DM. The National Health and Morbidity Survey (NHMS) in 2015 reported that the prevalence of T2DM was 17.5%,² which was similar to findings from The Malaysian Cohort (TMC) study that showed a prevalence of 16.6%.³ Based on the latest NHMS in 2019, one in five adults or equivalent to 3.9 million people aged 18 years and above in Malaysia have diabetes.⁴ The prevalence of diabetes had increased from 13.4% in 2015 to 18.3% in 2019.⁴ Early diagnosis is vital for diabetic patients, hence, intervention and treatment can be commenced immediately to prevent macrovascular or microvascular complications of diabetes.

Fasting plasma glucose (FPG) and oral glucose tolerance test (OGTT) have been used as the primary screening tools to diagnose diabetes.⁵ FPG, however, is commonly used in both clinical and epidemiological studies due to the inconsistency of the OGT results that rely on the 2-hour post glucose load (2HPG) which is also laborious to perform.⁶ Glycated hemoglobin (HbA1c) is a form of hemoglobin (Hb), produced by non-enzymatic reaction, chemically linked to a sugar and indicative of increased blood sugar in the body over the past 3-4 months.⁷ The use of HbA1c in monitoring or controlling the glucose metabolism was proposed by Anthony Cerami and colleagues in 1976.⁸ Unlike FBG and 2HPC, HbA1c detection is more convenient and patients do not need to fast overnight. In addition, is more accurate and convenient, with less pre-analytical and analytical variability.

The use of HbA1c to diagnose diabetes has been widely recommended and this is further expedited by the worldwide standardization of the HbA1c measurement.⁹ In 2009, the diagnosis of diabetes using HbA1c was proposed by the International Expert Committee¹⁰ and was
endorsed by both ADA and WHO in 2011. Nonetheless, there is evidence showing that HbA1c level varies between different ethnicities or populations. For example, Asians have been reported to have higher HbA1c levels than Caucasians. A recent study on the Vietnamese population by Ho-Pham et al., showed that the prevalence of pre-diabetes was about three times higher using the globally recommended HbA1c level of 6.5% or more as compared to using FPG. The prevalence of diabetes and pre-diabetes based on the HbA1c from the Ho Chi Minh City, Vietnam was 9.7% and 34.6% respectively. In Korea, Lee Kim and colleagues studied 35,624 non-diabetic Koreans and 1,491 participants were identified as newly diagnosed diabetes.

From these 1,491 participants, 31.6% met the FPG criteria only (≥7.0 mmol/l), 23.5% met HbA1c only (≥6.5%) and 44.9% met both FPG and HbA1c. In Malaysia, Nazaimoon and colleagues studied 4,341 individuals from five zones based on the WHO criteria that consists of 106,527 persons whose data infers that of the Malaysian population based on the Census Malaysia Report of 2000. Furthermore, our previous finding indicated that 16.6% of TMC participants were diabetic. Based on this prevalence, with 95% confidence interval and 80% power of study, the sample size needed for this study is only 214. However, since 40,667 participants were eligible, all participants were included into this study. The study was approved by the Research and Ethics Committee, Universiti Kebangsaan Malaysia (UKM) (FT-205-2007), in accordance with the declaration of Helsinki. Written informed consent was taken from all subjects.

**METHODOLOGY**

**Study design, study participants and sample size**

This study was derived from the prospective cohort study that consists of 106,527 persons whose data infers that of the Malaysian population based on the Census Malaysia Report of 2000. Furthermore, our previous finding indicated that 16.6% of TMC participants were diabetic. Based on this prevalence, with 95% confidence interval and 80% power of study, the sample size needed for this study is only 214. However, since 40,667 participants were eligible, all participants were included into this study. The study was approved by the Research and Ethics Committee, Universiti Kebangsaan Malaysia (UKM) (FT-205-2007), in accordance with the declaration of Helsinki. Written informed consent was taken from all subjects.

**Data collection**

Anthropometric measurements recorded for each participant included body mass index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR). Weight and height were obtained using a Seca weight scale (SECA, Jerman) and Harpenden stadiometer (Holtain Limited, UK) respectively. Blood pressure was measured using Omron HEM-907 (Omron Corporation, Japan). All measurements were performed three times and the average measurements were recorded. Each participant was interviewed face-to-face by a trained interviewer. Data obtained included age, gender, ethnicity and history of diabetes and other diseases.

**Blood collection and bioanalytical analysis**

Peripheral blood samples were collected by venipuncture from each participant after an overnight fasting. Biochemical analysis was performed within 24 hours post-blood collection. The blood sample for HbA1c was collected in the EDTA tube whereas the sample for FPG was collected in the sodium fluoride tube. For full lipid profile (total cholesterol, high density lipoprotein (HDL-c) and low-density lipoprotein (LDL-c), samples were collected using the SST II Advance vacutainer. FPG and full lipid profile were analyzed using the COBAS Integra® 800 (Roche Diagnostics Gmbh, Germany). Quality control was performed using Lyphochek Assayed Chemistry Control form Bio-Rad Laboratories. HbA1c was analyzed using the high-performance liquid chromatography (HPLC) in the VariantTM II Turbo machine (Bio-Rad Laboratories Inc, USA). Quality control was performed using Liquichek™ Diabetes Control form Bio-Rad Laboratories. All analyses were performed according to the protocols recommended by the manufacturer.

Subjects with a FPG concentration greater than or equal to 7.0 mmol/l were classified as having T2DM, those with levels between 6.1–6.9 mmol/l as pre-diabetes and level less than 6.1 mmol/l as normal. For HbA1c, those with values at 6.5% and above were classified as T2DM, values between 6.0–6.4% were deemed to have pre-diabetes and values less than 6.0% defined as normal. As for full lipid profile, total cholesterol levels of more than 5.2 mmol/l were classified as elevated and less than 5.2 mmol/l as normal, HDL more than 1.6 were classified as normal and less than 1.6 as deficient, while LDL less than 1.7 were classified as normal and more than 1.7 were classified as elevated. The tests were performed in an accredited bioanalytical laboratory.

**Statistical analysis**

The prevalence of diabetes and pre-diabetes was determined by percentage. The differences between groups were assessed using the Chi-square test for categorical data and ANOVA for continuous data. The association and agreement between HbA1c and FPG were assessed by Pearson correlation and Cohen’s kappa. The diagnostic test including sensitivity, specificity and accuracy of HbA1c in relative to FPG were determined using MedCalc Software. A p-value threshold of 0.05 was used for declaring significance. All analyses were performed using IBM SPSS Statistics 21.

**RESULTS**

**Population characteristics**

A total of 40,667 subjects were enrolled in this study with the mean age of 51.8 ± 8.2 years. Table 1 shows the status of pre-diabetes and diabetes according to the FPG and HbA1c levels in three Malaysian major ethnic groups including Malay, Chinese and Indian. Based on the FPG measurement, 10.6% and 5.7% of TMC participants were classified as having pre-diabetes and diabetes, respectively. When the HbA1c measurement was used, we observed significant increases in the prevalence of pre-diabetes (14.2%) and diabetes (7.5%). There were significant differences (p<0.001) between diabetes, pre-diabetes and normoglycaemia using the FPG and HbA1c diagnostic criteria for all characteristics (Table 1).

We also examined the relation between the prevalence of diabetes and ethnicity using both criterions. Using the FPG, we noticed that diabetes was more prevalent among Indians (8.3%), followed by Malay (7.0%) and Chinese (3.2%). The pattern was similar when we employed the HbA1c level measurement as the diagnostic tool. However, we observed that the diabetes prevalence in each ethnic group was higher...
shows the concordance in the classification of diabetes based on FPG criteria. Of the 3,060 individuals with diabetes according to the HbA1c criteria, only 1,781 (58.2%) were concordantly classified as diabetes based on FPG criteria. Table 2 shows the concordance in the classification of diabetes and pre-diabetes between HbA1c and FPG. Out of 5,778 subjects diagnosed with pre-diabetes based on HbA1c diagnostic criterion, 1,462 (25.3%) had similar diagnosis based on FPG. Using HbA1c alone, pre-diabetes was diagnosed about 30% greater than the FPG, and almost 2-fold for diabetes (Table 1). There was a moderate agreement between the diagnosis of diabetes by HbA1c and FPG (Kappa=0.64, p<0.001), whilst the agreement for pre-diabetes was poor (Kappa=0.19, p<0.001). The use of HbA1c level of ≥6.5% to diagnose diabetes led to a sensitivity of 58.2% and a specificity of 98.59%, with a positive predictive value of 96.67% compared to FPG where 12.43% of Indians were classified as diabetes, followed by Malay (8.95%) and Chinese (4.23%). In addition, the prevalence of diabetes was higher among those in the rural areas compared to the urban population using both FPG and HbA1c criteria (p<0.001).

For the mean systolic blood pressure, the patients with diabetes using FBG, had higher readings compared to normal and pre-diabetes subjects. The mean total cholesterol (TC) and LDL cholesterol levels showed increasing trends as the plasma glucose increases across the glucose tolerance groups using either FPG or HbA1c. Obesity, indicated by the increase in body mass index (BMI), waist circumference and waist hip ratio, is associated with high-risk of developing diabetes. In line with this, we observed that those who have diabetes, diagnosed using either FPG or HbA1c criteria, have larger waist circumference, higher BMI and WHR compared to normal and pre-diabetes subjects (Table 1).

**Correlation and concordance between HbA1c and FPG**

Of the 3,060 individuals with diabetes according to the HbA1c criteria, only 1,781 (58.2%) were concordantly classified as diabetes based on FPG criteria. Table 2 shows the concordance in the classification of diabetes and pre-diabetes based on HbA1c and FPG. Out of 5,778 subjects diagnosed with pre-diabetes based on HbA1c diagnostic criterion, 1,462 (25.3%) had similar diagnosis based on FPG. Using HbA1c alone, pre-diabetes was diagnosed about 30% greater than the FPG, and almost 2-fold for diabetes (Table 1). There was a moderate agreement between the diagnosis of diabetes by HbA1c and FPG (Kappa=0.64, p<0.001), whilst the agreement for pre-diabetes was poor (Kappa=0.19, p<0.001). There was a highly significant correlation between HbA1c and FPG, as shown in Figure 1 (r²=0.86; P<0.001). The use of the HbA1c level of ≥6.5% to diagnose diabetes led to a sensitivity of 58.2% and a specificity of 98.59%, with a positive predictive value of 77.03% and a negative predictive value of 96.67% compared to FPG (Table 3).

### Table 1. Subjects characteristics and prevalence of pre-diabetes and diabetes using FPG and HbA1c

| Diagnosis Based on HbA1c | P-value | Diagnosis Based on HbA1c | Normal | Pre-diabetes | Diabetes | Total |
|--------------------------|---------|--------------------------|--------|--------------|----------|-------|
| Normal                   |         |                          | 1,119  | 1,779        | 3,060    | 5,778 |
| Pre-diabetes             |         |                          | 1,119  | 1,779        | 3,060    | 5,778 |
| Diabetes                 |         |                          |        |              |          |       |

**Table 2. Concordance in diagnostic classification between HbA1c and FPG**

| Diagnosis Based on FBG | Diagnosis Based on HbA1c | Normal | Pre-diabetes | Diabetes | Total |
|------------------------|--------------------------|--------|--------------|----------|-------|
| Normal                 |                          | 5,778  | 3,060        | 0        |       |
| Pre-diabetes           |                          | 5,778  | 3,060        | 0        |       |
| Diabetes               |                          | 5,778  | 3,060        | 0        |       |

**Table 3.** Concordance in diagnostic classification between HbA1c and FPG
Although this study showed a high correlation \( r^2 = 0.86 \) and moderate agreement between fasting plasma glucose and HbA1c in the diagnosis of diabetes, the two tests showed a poor agreement in detecting pre-diabetes. Discordance in the diagnosis of diabetes between HbA1c and FPG screening methods have been reported mainly among Asian populations. A smaller scale population-based study in Malaysia about a decade ago involving 4,341 subjects showed consistent results with the studies from other Asian populations. The discordance might be explained by the different information given by both HbA1c and FPG on the glycaemic exposure. FPG is the measurement of blood glucose at the particular time point, whereas HbA1c reflects the blood glucose level for the past 3 months. It is suggested that the use of HbA1c can avoid the problem of within-subject fluctuation in glucose measurements. Thus, it is not surprising that individuals were classified differently by both methods based on the exposure of the blood glucose. It is also important to be aware about the different processes involved in measuring HbA1c and FPG, and the variation in the glycation process between individuals which might also contribute to the variations.

The findings of this present study are likely to be representative of the actual diabetes prevalence in the general population who come from different ethnic groups. A study by Booth and colleagues in Canada showed similar findings where different ethnic groups will have different HbA1c levels in order to detect dysglycemia or diabetes.

Measuring HbA1c is a convenient approach for diabetes diagnosis due to its pre-analytical stability, less intra-individual variability and more importantly, unlike the oral glucose tolerance test, HbA1c level measurement does not require an overnight fast. However, there are several limitations using HbA1c for the diagnosis of diabetes. First, HbA1c cannot be used in individuals with haemoglobinopathies, anemia and disorders where the patients had abnormal red cell turnover. Other processes such as erythropoiesis, glycation, erythrocyte destruction as well as different HbA1c assays used may also lead to differences in the HbA1c levels.

For example, in erythrocyte destruction, increased erythrocyte life span and splenectomy could lead to increase HbA1c levels, whereas decreased erythrocyte life span, haemoglobinopathies, splenomegaly, rheumatoid arthritis or drugs such as anti-retrovirals, ribavirin and dapsone may decreased HbA1c levels.

Appendix 1 shows several factors that could influence the HbA1c measurement and Appendix 2 shows the advantages and disadvantages of glucose and HbA1c assays (adapted from Gallagher et al., and WHO, 2011). Based on the WHO report in 2011, HbA1c can be used when rigorous quality assurance tests are applied, the assays are standardized based on the international reference value and the diabetic patients have no conditions as mentioned above that could result in imprecise measurement. In addition, The American Association of Clinical Endocrinologists recommended that the HbA1c test should be considered as an additional, not as a primary diagnostic criterion.
CONCLUSION
In summary, our results showed a higher prevalence of pre-diabetes and diabetes upon using the HbA1c compared to FPG. We also showed the differences in prevalence of diabetes across the different ethnic groups. We believe there is a basis to use the HbA1c for diagnosis of pre-diabetes and diabetes among the Malaysian population for early intervention and prevention. However, given that HbA1c may also led to lower specificity and high false positive rate, several criteria should be used in diagnosing and controlling diabetes.

Acknowledgments
The authors would like to thank all the members of The Malaysian Cohort (TMC) Study Group, UMBI staff and the participants involved in this project, as well as the community leaders and officers from the local authorities who have assisted in the recruitment processes.

Statement of Authorship
All authors certified fulfillment of ICMJE authorship criteria.

Author Disclosure
The authors declared no conflicts of interest.

Funding Source
This research was funded by a top-down grant from the Ministry of Higher Education (MOHE) Malaysia, grant number PDE48. This study was approved by the Research Ethics Committee UKM of Higher Education (MOHE) Malaysia, grant number PDE48.

Author Disclosure
The authors declared no conflicts of interest.

Statement of Authorship
All authors certified fulfillment of ICMJE authorship criteria.

Author Disclosure
The authors disclosed no conflicts of interest.

Funding Source
This research was funded by a top-down grant from the Ministry of Higher Education (MOHE) Malaysia, grant number PDE48. This study was approved by the Research Ethics Committee UKM of Higher Education (MOHE) Malaysia, grant number PDE48.

References
1. Adeghate E, Shattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006;1084:1-29. PMID: 17151290. https://doi.org/10.1196/can.137.029.
2. Institute for Public Health (IPI) 2015. National Health and Morbidity Survey 2015 (NHMS 2015). Non-communicable diseases, risk factors and other health problems. Vol. 2. Kuala Lumpur, Malaysia. 2015:1-315. Available from: https://www.moh.gov.my/moh/resources/nhmsreport2015vol2.pdf.
3. Jamal R, Syed Zakaria SZ, Kamaruddin MA, et al. The Malaysian Cohort (TMC) project: A prospective study of non-communicable diseases in a multiethnic population. Int J Epidemiology. 2015;44(2):423-31. PMID: 24729425. PMCID:PMC4469794. https://doi.org/10.1093/ije/dyu889.
4. Institute for Public Health (IPI) 2019. National Health and Morbidity Survey 2019 (NHMS 2019). National Health and Morbidity Survey 2019. Non-communicable diseases, healthcare demand, and health literacy. Key findings. Available at http://www.iku.gov.my/nhms.
5. Ashraf S. Diagnosis of type 2 diabetes using serial fasting plasma glucose versus HbA1c in the primary care setting. Aust J Gen Pract. 2019;48(5):269-71. PMID: 3112936. https://doi.org/10.3112/AJGP.07-18.4652.
6. Modhumi Khan RM, Yu Chua ZJ, Tan JC, Yang Y, Liao Z, Zhao Y. From pre-diabetes to diabetes: Diagnosis, treatments and translational research. Medicina (Kaunas). 2019;55(9):546. PMID: 31470636. PMCID: PMC6780263. https://doi.org/10.3390/medicina55090546.
7. Ye Y, Xie H, Zhao X, Zhang S. The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: A meta-analysis of diagnostic test accuracy. Cardiovasc Diabetol. 2012;11:155. PMID:23274530. PMCID:PMC3334887. https://doi.org/10.1186/1475-2840-11-155.
8. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: Abbreviated report of a WHO Consultation. Geneva: World Health Organization. 2011. PMID: 22158184. Bookshelf ID:BNBK304267.
9. Peterson RP, Pavlovich BD, Goldstein D, Lim J, Peterson CM. What is hemoglobin A1c? An analysis of glycated hemoglobin by electrospray ionization mass spectrometry. Clin Chem. 1998;44(9):1951-8. PMID:9752983.
10. Koening RJ, Peterson CM, Jones RL, et al. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med. 1976;295(8):417-20. PMID: 934240. https://doi.org/10.1056/NEJM197608192950804.
11. Trevor G. Consensus statement on the worldwide standardization of the haemoglobin A1c measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation: Response to the Consensus Committee. Diabetes Care. 2007;30(12):e141. PMID: 18042750. https://doi.org/10.2337/dc07-1752.
12. International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-34. PMID: 19502545. PMCID: PMC2669715. https://doi.org/10.2337/dc09-9033.
13. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: Abbreviated report of a WHO consultation. Geneva: World Health Organization; 2011. Bookshelf ID:BNBK304267.
14. Wang B, Liu MC, Li XY, et al. Cutoff point of HbA1c for diagnosis of diabetes mellitus in Chinese individuals. PLoS One. 2016;11(11):e0166597. PMID:22786159. PMCID:PMC5115764. https://doi.org/10.1371/journal.pone.0166597.
15. Nam HK, Cho WK, Kim JH, et al. HbA1c cutoff for prediabetes and diabetes based on oral glucose tolerance test in obese children and adolescents. J Korean Med Sci. 2018;33(12):e93. PMID: 29542302. PMCID:PMC5852422. https://doi.org/10.3346/jkms.2018.33.e93.
16. Wan Nazaimon WM, Md Isha SH, Wan Mohamad WB, et al. Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion. Diabet Med. 2013; 30(7):828-5. PMID: 23413941. https://doi.org/10.1111/dme.12161.
17. Lim WY, Ma S, Heng D, Tai ES, Khoo CM, Loh TP. Screening for diabetes with HbA1C: Test performance of HbA1c compared to fasting plasma glucose among Chinese, Malay and Indian community residents in Singapore. Sci Rep. 2018; 8(1):12419. PMID: 30127499. PMCID: PMC6102285. https://doi.org/10.1186/s12985-018-2998-y.
18. Herman WH, Dungan KM, Wolfenbuttel BHR, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94(5):1699-94. PMID:19276225. https://doi.org/10.1210/jc.2008-1940.
19. Ho-Pham LT, Nguyen UDT, Tran TX, Tran NG, TV. Discordance in the diagnosis of diabetes: Comparison between HbA1c and fasting plasma glucose. PLoS ONE. 2017; 12(8):e0182192. PMID: 28817663. PMCID:PMC5650685. https://doi.org/10.1371/journal.pone.0182192.
20. Kim HK, Kim CH, Kim EU, Bae SJ, Park JY. Usefulness of hemoglobin A1c as a criterion of dysglycemia in the definition of metabolic syndrome in Koreans. Diabetes Res Clin Pract. 2012; 95(3):333-9. PMID: 22574343. PMCID:PMC3560685. https://doi.org/10.1016/j.diabres.2011.10.012.
21. Unwin N, Howitt C, Mc Rose A, Samuels TA, Hennis AJ, Hambleton IR. Prevalence and phenotype of diabetes and prediabetes using fasting glucose vs HbA1c in a Caribbean population. J Glob Health. 2017;7(2):020407. PMID: 28959440. PMCID: PMC5040988. https://doi.org/10.7189/jogh.070204.
22. Hudson PR, Child DF, Jones H, Williams CP. Differences in rates of glycation (glycation index) may significantly affect individual HbA1c results in type 1 diabetes. Ann Clin Biochem. 1999; 36(Pt 4):451-9. PMID:10456207. https://doi.org/10.1111/j.1365-2645.1999.tb04309.x.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care.2010; 33 (Suppl 1):S26-9. PMID: 24532715. https://doi.org/10.2337/dc10-1488.
24. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A1c in the management of diabetes. J Diabetes. 2009;1(1):9-17. PMID: 20923315. https://doi.org/10.1111/j.1753-043X.2009.00099.x.
25. American Association of Clinical Endocrinologists/American College of Endocrinology Statement on the use of hemoglobin A1C for the diagnosis of diabetes. AACE/ACE Position Statement. 2010;16(2): 155-6. https://doi.org/10.4158/EP.16.2.155.
APPENDICES

Appendix 1. Several factors that could influence HbA1c levels\(^2\) (adapted)

| Description                | Increased HbA1c                                                                 | Decreased HbA1c                                                                 |
|----------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Erythropoiesis             | iron, vitamin B12 deficiency, decreased erythropoiesis                        | administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic liver disease |
| Altered Haemoglobin        | genetic or chemical alterations in haemoglobin: haemoglobinopathies, HbF, methaemoglobin, may increase or decrease HbA1c. |                                                                                   |
| Glycation                  | alcoholism, chronic renal failure, decreased intra-erythrocyte pH             | ascorbin, vitamin C and E, certain haemoglobinopathies, increased intra-erythrocyte pH, variable HbA1c; genetic determinants. |
| Erythrocyte destruction    | increased erythrocyte life span: Splenectomy                                  | decreased erythrocyte life span: haemoglobinopathies splenomegaly, rheumatoid arthritis or drugs such as antiretrovirals, ribavirin and dapsone |
| Assays                     | hyperbilirubinaemia, carbamylated haemoglobin, alcoholism, large doses of aspirin, chronic opiate use, variable HbA1c; haemoglobinopathies. | hypertriglyceridaemia                                                             |

Appendix 2. Advantages and disadvantages of glucose and HbA1c assays in the diagnosis of diabetes\(^13\)

| Description                                      | Glucose                                                                 | HbA1c                                                                 |
|--------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Patient preparation prior to collection of blood | Stringent requirements if measured for diagnostic purposes             | None                                                                  |
| Processing of blood                              | Stringent requirements for rapid processing, separation and storage of plasma or serum at 4°C | Avoid conditions for more than 12 hr at temperatures >23°C. Otherwise keep at 4°C (stability minimally 1 week). |
| Measurement                                      | Widely available                                                        | Not readily available world-wide                                       |
| Standardization                                  | Standardization for procedures is needed                                 | Standardization for procedures is needed                               |
| Routine calibration                              | Adequate                                                                | Adequate                                                              |
| Interferences: Illness                          | Severe illness may increase glucose concentration                       | Severe illness may shorten red-cell life and could reduce HbA1c levels |
| Haemoglobinopathies                              | Less problematic unless the patient is ill                              | May interfere with measurement in some assays                           |
| Haemoglobinopathy traits                         | No problems                                                             | Not affected by most assays                                             |
| Affordability                                    | Affordable in most low and middle income country settings (Cheap)       | Unaffordable in most low and middle-income country settings (Expensive) |

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights, and that no references have been made to predatory/suspected predatory journals; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license; and (5) the Conversion to Visual Abstracts (optional for original articles only) to improve dissemination to practitioners and lay readers. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.

www.asean-endocrinejournal.org